



55-248 60 150

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

JUL 14 1997

GROUP 1500

Applicant: Lisbeth Illum

Serial No: Divisional of
U.S.S.N. 08/359,937

08/877,273

Art Unit: To be assigned

3

Filing date: June 17, 1997

Examiner: To be assigned

For: SMALL PARTICLE COMPOSITIONS FOR
INTRANASAL DRUG DELIVERY

Assistant Commissioner of Patents
Washington, D.C. 20231

RECEIVED
ALLOWED FOR PUBLICATION
JUL 14 1997

6110
7/31

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE
PATENTING REJECTION OVER A PATENT

Sir:

Danbiosyst UK Limited is the owner of the entire interest in the above-identified application as evidenced by the accompanying certificate under 37 C.F.R. § 3.73(b). Danbiosyst UK Limited hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154-156 and 173 of U.S. Patent No. 5,204,108 which issued April 20, 1993. Danbiosyst UK Limited hereby agrees that any patent so granted on the instant application shall be enforceable only for and

RECEIVED
ALLOWED FOR PUBLICATION
JUL 14 1997

07/10/1997 061850N 0000010290359922.00 01 FC:248

Divisional of U.S.S.N. 08/359,937
Filed: June 17, 1997
Terminal Disclaimer to Obviate for
Intranasal Drug Delivery

during such period that it and U.S. Patent No. 5,204,108 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Danbiosyst UK Limited does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154-156 and 173 of U.S. Patent No. 5,204,108, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned (whose title is supplied below) is empowered to act on behalf of Danbiosyst UK Limited.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the

Divisional of U.S.S.N. 08/359,937
Filed: June 17, 1997
Terminal Disclaimer to Obviate for
Intranasal Drug Delivery

United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

DANBIOSYST UK LIMITED

By: _____



Patrea L. Pabst
Registration Number 31,284
Attorney on behalf of Danbiosyst UK Limited

Date: June 17, 1997